Structural Biology Program
The Nikola Pavletich Lab
Our research group is interested in the structural biology of pathways that are altered in cancer, with particular emphasis on pathways that control the growth and proliferation of the cell. In cancer, mutations and other alterations in these pathways lead to the uncoupling of cell growth from growth-regulatory signals and contribute to the unrestricted proliferation of the tumor cell.
Yang, H., Rudge, D.G., Koos, J.D., Vaidialingam, B., Yang, H.J. & Pavletich, N.P. mTOR kinase structure, mechanism and regulation. Nature 497, 217-223 (2013).
Wang, R., Persky, N., Yoo, B., Ouerfelli, O., Smogorzewska, A., Elledge, S. J. & Pavletich, N.P. Mechanism of DNA interstrand cross-link processing by repair nuclease FAN1. Science 346, 1127-30 (2014).
Zhou, C., Pourmal, S. & Pavletich, N. P. Dna2 nuclease-helicase structure, mechanism and regulation by Rpa. eLife 4:e09832 (2015).
Yang, H., Jiang, X., Li, B., Yang, H.J., Miller, M., Yang, A., Dhar, A. & Pavletich, N.P. Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40. Nature 552, 368-373 (2017).
Nikola P. Pavletich, PhD
- The Pavletich laboratory studies the structural biology of oncogenes and tumor suppressors.
- PhD, Johns Hopkins University
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Nikola P. Pavletich discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.